Dengue virus serotype 3 pre-membrane protein (DENV-3 prM)

The Dengue virus serotype 3 pre-membrane (prM) protein is a critical structural glycoprotein essential for the assembly and maturation of infectious DENV-3 particles (UniProt: P27915). It functions primarily as a molecular chaperone for the envelope (E) protein, forming prM-E heterodimers that shield the E protein's fusion loop from premature activation within the acidic environment of the host cell's secretory pathway (Pierson & Diamond, 2012). During the final stages of viral egress, the host protease furin cleaves prM into the 'pr' peptide and the mature 'M' protein, a transition that renders the virion infectious (NCBI: TaxID 11069). In clinical medicine, prM is a significant target for the immune system, though antibodies directed against it are frequently cross-reactive and poorly neutralizing, which can contribute to antibody-dependent enhancement (ADE) and more severe disease outcomes like Dengue Hemorrhagic Fever (Halstead, 2003). Consequently, prM is a key component in the design of tetravalent vaccines, such as Dengvaxia and Qdenga, which aim to elicit protective immunity across all four dengue serotypes (World Health Organization, 2023). Therapeutic strategies focusing on prM often involve neutralizing antibodies or small molecules designed to interfere with the prM-to-M cleavage process or the stability of the prM-E complex.

Other names

Pre-membrane proteinprM proteinDengue virus 3 prMDENV3 prMpM

Induction of neutralizing antibodies and T-cell responses that target the viral surface to inhibit attachment, fusion, and entry into host cells (World Health Organization, 2023; Sanofi Pasteur, 2015).